Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
US Department of Justice
Mallinckrodt
Chinese Patent Office
QuintilesIMS
Julphar
Colorcon
Fish and Richardson

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,637,079

« Back to Dashboard

Which drugs does patent 8,637,079 protect, and when does it expire?

Patent 8,637,079 protects OSENI and is included in one NDA.

This patent has thirty-eight patent family members in thirty-six countries.
Summary for Patent: 8,637,079
Title:Solid preparation comprising alogliptin and pioglitazone
Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
Inventor(s): Nakamura; Kenji (Osaka, JP), Kiyoshima; Kenichiro (Osaka, JP), Nomura; Junya (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/449,255
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,637,079

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-005 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-006 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,637,079

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-023594Feb 1, 2007
PCT Information
PCT FiledJanuary 30, 2008PCT Application Number:PCT/JP2008/051900
PCT Publication Date:August 07, 2008PCT Publication Number: WO2008/093882

International Patents Family Members for US Patent 8,637,079

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 065097 ➤ Try a Free Trial
Austria 488227 ➤ Try a Free Trial
Australia 2008211981 ➤ Try a Free Trial
Brazil PI0807453 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Cantor Fitzgerald
AstraZeneca
Chinese Patent Office
Cipla
McKesson
Julphar
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.